Hologic’s (HOLX) “Outperform” Rating Reiterated at William Blair

Hologic (NASDAQ:HOLX)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a note issued to investors on Monday,RTT News reports.

Other equities analysts have also recently issued research reports about the company. Wolfe Research started coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Mizuho dropped their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Seven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Hologic Trading Down 2.0 %

Shares of NASDAQ:HOLX traded down $1.41 during trading on Monday, reaching $70.29. 3,100,719 shares of the stock were exchanged, compared to its average volume of 2,138,960. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic has a 12-month low of $69.46 and a 12-month high of $84.67. The firm has a market cap of $15.95 billion, a price-to-earnings ratio of 21.11, a price-to-earnings-growth ratio of 2.32 and a beta of 0.97. The firm’s 50-day moving average price is $75.88 and its 200 day moving average price is $78.55.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.89 EPS. On average, sell-side analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.75% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HOLX. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the 3rd quarter valued at about $25,000. General Partner Inc. acquired a new stake in Hologic in the 4th quarter valued at approximately $26,000. Groupama Asset Managment grew its holdings in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in Hologic in the 2nd quarter valued at approximately $37,000. Finally, First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.